<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03145402</url>
  </required_header>
  <id_info>
    <org_study_id>SCARM-Heart-001</org_study_id>
    <nct_id>NCT03145402</nct_id>
  </id_info>
  <brief_title>ICMNC-HF. IntraCoronary Bone Marrow MonoNuclear Cells in Heart Failure (HF) Patients</brief_title>
  <acronym>ICMNC-HF</acronym>
  <official_title>The Effect of Intracoronary Autologous Bone Marrow Derived Mononuclear Stem Cell Transplantation in Heart Failure (HF) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SCARM Institute, Tabriz, Iran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SCARM Institute, Tabriz, Iran</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomised double blind, controlled, parallel-group phase I and II
      study. Its aim is to assess that a single intracoronary infusion of autologous bone
      marrow-mononuclear cells is safe and effective in hear failure patients with reduced left
      ventricular ejection fraction(&lt;=30%) when compared to a control group of patients undergoing
      best medical care.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 20, 2018</start_date>
  <completion_date type="Anticipated">April 2, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>12 months</time_frame>
    <description>The rate of patients mortality after transplantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>12 months</time_frame>
    <description>the rate of hospitalization after transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ejection fraction changes</measure>
    <time_frame>12 months</time_frame>
    <description>Elevation of ejection fraction in patients after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk test (6MWT)</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation the improvement of 6MWT test after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pro b-type natriuretic peptide (Pro-BNP) changes</measure>
    <time_frame>12 months</time_frame>
    <description>Elevation the reduction of Pro-BNP in patients after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA functional class</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation the improvement of NYHA functional class in patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Intracoronary injection of stem cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous bone marrow-derived mononuclear cells injection in patients with Heart Failure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo injection via coronary arteries in patients with Heart Failure</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intracoronary injection of stem cell</intervention_name>
    <description>Autologous bone marrow-derived mononuclear cells are obtained from 100-150ml of bone marrow aspirated under local anaesthesia from the iliac crest. Intracoronary infusion of the cells is performed in patients with Heart failure via conventional percutaneous intracoronary intervention techniques.</description>
    <arm_group_label>Intracoronary injection of stem cell</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Injection of Placebo in patients with Heart failure via coronary arteries</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women of any ethnic origin 18 ≤ aged≤ 65 years

          2. EF≤40 (by Echocardiography) and regional wall motion abnormality

          3. Not responding to standard therapies

          4. the New York Heart Association (NYHA) class ≥ III

          5. Myocardial infarction due to coronary artery atherosclerotic disease

          6. An area of regional dysfunction, i.e., hypokinetic, akinetic, or dyskinetic
             (echocardiography or MRI)

          7. Normal liver and renal function

          8. No or controlled diabetes

          9. Able to give voluntary written consent and understand the study information provided
             to him

        Exclusion Criteria:

          1. Participation in another clinical trial within 30 days prior randomisation

          2. Previously received stem/progenitor cell therapy

          3. Pregnant women

          4. Mental condition rendering the patient unable to understand the nature, scope and
             possible consequences of the study or to follow the protocol

          5. Cardiogenic shock requiring mechanical support

          6. Congenital / valvular heart disease

          7. Implantable cardioverter defibrillator (ICD) transplant

          8. Platelet count &lt;100.000/µl, or hemoglobin &lt;8.5 g/dl

          9. Impaired renal function, i.e. creatinine &gt;2.5 mg/dl

         10. Fever or diarrhea within 4 weeks prior screening

         11. History of bleeding disorder within 3 months prior screening

         12. Uncontrolled hypertension (systolic &gt;180 mmHg and diastolic &gt;120 mmHg) or Sustained
             ventricular arrhythmia

         13. Life expectancy of less than two years from any non-cardiac cause or uncontrolled
             neoplastic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nasser Aslanabadi, MD, Cardiologist</last_name>
    <role>Study Director</role>
    <affiliation>Tabriz University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Nouri, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Head of SCARM institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peyman Keyhanvar, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deputy for translational medicine of SCARM institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raheleh Farahzadi, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular research center, Tabriz University of Medical Sciences, Tabriz, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yousef Faridvand, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>SCARM institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elgar Anamzadeh, MD, Cardiologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tabriz University of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nasser Aslanabadi, MD, Cardiologist</last_name>
    <phone>0413 33349525</phone>
    <email>aslanabadin@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peyman Keyhanvar, MD, Ph.D</last_name>
    <phone>0413 33349525</phone>
    <email>drkeyhanvar@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stem Cell And Regenerative Medicine institute (SCARM)</name>
      <address>
        <city>Tabriz</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peyman Keyhanvar, MD, Ph.D</last_name>
      <phone>0914 114 6863</phone>
    </contact>
    <investigator>
      <last_name>Yousef Faridvand, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2017</study_first_submitted>
  <study_first_submitted_qc>May 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

